Best Immunology Companies in Canada
The 39 best Immunology companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abcellera Biologics.
- Immunology Market size is set to grow by USD 56.07 billion from 2022 t
Ranked: Best Immunology companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abcellera Biologics AI-enabled platform for antibodies discovery | $115M | 62 mo ago | 560 | 2012 | — | WordPressMySQLRedis+29 | 6 signals ▲100% Earnings · Lawsuit | 50 patents Therapeutic antibody discovery using transgenic rodents and computational affinity modeling | 1 partnership |
| 2 | Aurinia Pharmaceuticals Developer of therapeutics for autoimmune diseases | $96M | 116 mo ago | 17 | 1993 | — | Apple iCloud MailMicrosoft 365Zoho+16 | 31 signals Leadership · Earnings · M&A | 111 patents Immunosuppressive small‑molecule therapies targeting lupus nephritis, e.g., voclosporin and BAFF/APR inhibitors. | — |
| 3 | Aquinox Pharma Small molecule targeting PI3K pathway. | $71M | 161 mo ago | — | 2004 | — | — | — | — | — |
| 4 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 23 mo ago | 11 | 2020 | — | WordPress Block EditorWordPressMySQL+16 | — | 38 patents Multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 5 | SQI Diagnostics Developer of multiplexed tests and automated systems for biological testing. | $37M | 45 mo ago | 70 | 1999 | — | — | — | 75 patents Multiplexed microarray immunoassay analysis and quantitative detection platforms | — |
| 6 | Ability Developer of modulating biotherapeutics to address cancer and autoimmune diseases | $30M | 26 mo ago | — | 2023 | Jean Buerckert Co-Founder & CTO | WordPressMySQLPHP+9 | — | — | — |
| 7 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 53 mo ago | 22 | 2007 | — | WordPressMySQLPHP+20 | — | 80 patents Innate immune modulation for adoptive cell therapies and perioperative cancer treatment | — |
| 8 | Revive Therapeutics Developer of therapeutics to treat rare and infectious diseases 27Product top 24%Moat top 32%Funding top 36%Patents top 42% All 10 signals ▾Producttop 24% Moattop 32% Fundingtop 36% Patentstop 42% Innovationtop 44% Growthtop 48% Techbottom 48% Newsbottom 43% Globalbottom 31% Marketbottom 16% Product: 2 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $17M | 12 mo ago | 3 | 2012 | — | WordPressMySQLPHP+16 | — | 24 patents Therapeutic neuropharmacology using psilocybin and bucillamine for brain injury, stroke, migraines, and infections | — |
| 9 | Allostera Pharma New class of pre-clinical drugs, called Allosteramers primarily focused on inflammation and autoimmunity | $16M | 205 mo ago | — | 2006 | Sylvain Chemtob Co-Founder | — | — | — | — |
| 10 | Giiant Pharma Developer of colon-specific anti-inflammatory therapy for ulcerative colitis | $12M | 62 mo ago | 4 | 2014 | — | — | — | — | — |
| 11 | Reverb Therapeutics Developer of treatments for cancer and other diseases | $12M | 18 mo ago | — | 2022 | Surjit Dixit Co-Founder | Wix eCommerceWixSentry+14 | — | — | — |
| 12 | Devonian Developer of drugs for inflammatory disease and dermatology 19Funding top 38%News top 45%Growth top 48%Global bottom 25% All 5 signals ▾Fundingtop 38% Newstop 45% Growthtop 48% Globalbottom 25% Marketbottom 23% Funding: Raised $11.5M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) News: 6 BI events in 12 mo (of 71 tracked, 8 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 19/100 | $12M | 13 mo ago | 7 | 2013 | — | — | 6 signals ▼25% Announcements · Earnings | — | — |
| 13 | Kenota Health Developer of immunological testing kits | $11M | 69 mo ago | 45 | 2014 | Moufeed Kaddoura Founder & CEO | WordPressMySQLPHP+19 | — | — | — |
| 14 | Find Therapeutics Developer of targeted therapies modulating membrane receptors for autoimmune diseases | $8M | 23 mo ago | 8 | 2017 | Philippe Douville Chief Executive Officer | — | — | — | — |
| 15 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 18 mo ago | 9 | 2019 | Yulong Sun Co-Founder | — | — | 5 patents Monoclonal antibodies specific for conformational epitopes of lambda immunoglobulin light chains | — |
| 16 | Edesa Biotech Developer of topical therapeutics for dermatological and gastrointestinal diseases | $7M | 18 mo ago | 16 | 2015 | Par Nijhawan Founder & CEO | WordPressMySQLPHP+16 | — | 8 patents Peptide-based therapeutics for vitiligo and acute respiratory distress syndrome | — |
| 17 | Vitaeris Monoclonal Antibodies (MAbs) for inflammatory diseases | $7M | 123 mo ago | 11 | 2016 | — | — | — | 31 patents Therapeutic anti‑IL‑6 antibodies for transplant desensitization and COVID‑19 ARDS treatment | — |
| 18 | Atreus Pharmaceuticals Developing in vivo imaging diagnostic candidates for autoimmune diseases | $6M | 198 mo ago | — | 2007 | Bill Dickie CEO | — | — | — | — |
| 19 | BirchBioMed Developer of anti-scarring drugs and autoimmune therapies | $6M | 14 mo ago | 6 | 2014 | — | — | — | 16 patents Topical small‑molecule anti‑aging and scar‑reduction cosmetics for skin wrinkles and atrophic scars | — |
| 20 | Encycle Therapeutics Peptide mimetics to target protein-protein interactions to treat inflammatory bowel disease and fibrosis. | $6M | 131 mo ago | 6 | 2012 | — | — | — | 23 patents Design and synthesis of homodetic cyclic peptide therapeutics targeting α4β7 integrin | — |
| 21 | Augurex Developer of diagnostic tests to detect autoimmune and chronic diseases | $978K | 186 mo ago | 20 | 2006 | — | WordPressMySQLPHP+26 | — | — | — |
| 22 | Aurin Biotech Develops drugs that can block self-attack by the body’s complement system due to diseases | $795K | 100 mo ago | 2 | 2012 | Patrick McGeer Co-Founder | — | — | 44 patents Patents concentrated in health & consumer products | — |
| 23 | ImmunoFlex Developer of products to improve immunity | $500K | 66 mo ago | 2 | 2020 | — | — | — | — | — |
| 24 | Naegis Pharmaceuticals Developer of therapies for the treatment of chronic inflammation | $351K | 28 mo ago | — | 2010 | David Burgoyne Founder & CEO | — | — | 14 patents Novel small‑molecule inhibitors targeting leukotriene biosynthesis for anti‑inflammatory therapy. | — |
| 25 | Avro Lifesciences Developer of dermal therapies and patches for pediatric use | $150K | 102 mo ago | 19 | 2016 | — | — | — | — | — |
| 26 | Modulari-T Biosciences Developer of cell therapies for immune disorders | $125K | 38 mo ago | 5 | 2020 | David White Co-Founder | WordPressMySQLPHP+16 | — | — | — |
Top 12 Immunology companies in Canada
#1
Public · Toronto, Ontario · founded 2012 · 3 employees$16.8Mraised▾
Developer of therapeutics to treat rare and infectious diseases. Its lead product Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) helps in treating infectious diseases, including COVID-19, influenza, and others. Also has psilocybin for multiple indications.
- Aug 2025Post IPO$110.7K
- Apr 2025Post IPO$120.2K
- Jan 2024Post IPO$1.6M
- Jan 2023Post IPO$4.3M
#2
Public · Quebec City, Quebec · founded 2013 · 7 employees$11.5Mraised▾
Developer of drugs for inflammatory diseases and dermatology. The flagship product, Thykamine, has shown anti-inflammatory and anti-oxidant properties, as per company claims, and is currently under development for the treatment of ulcerative colitis, atopic dermatitis, eczema, and psoriasis. The company also develops cosmetic products which include anti-aging products, and sun care products for women and men.
- Aug 2025Post IPO$1.7M
- Mar 2024Post IPO$166K
- May 2023Post IPO$889.6K
- Nov 2021Post IPO$2.3M
#3
Series A · Toronto, Ontario · founded 2014 · 6 employees$5.9Mraised▾
Developer of anti-scarring drugs and autoimmune therapies. It offers a lead candidate AI-001 which uses a single dose of allogeneic cells injected into the patient for treatment of Type-1 Diabetes, Psoriasis and Alopecia.
- Jun 2025Series A$2.5M
- Oct 2021Series A$596K
- Feb 2020Series A$5.3M
#4
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
- Sep 2024Series A$35M
- Apr 2023Seed$8M
#5
Seed · Vancouver, British Columbia · founded 2022$12Mraised▾
Developer of treatments for cancer and other diseases. It offers Amplifier Antibody platform that avoids the systemic toxicity normally associated with cytokine treatments by increasing cytokine levels only in targeted tissues.
- Feb 2025Seed$12M
- Nov 2023Seed—
#6
Public · Toronto, Ontario · founded 2015 · 16 employees$7Mraised▾
Developer of topical therapeutics for dermatological and gastrointestinal diseases. It is developing therapeutics for diseases such as contact dermatitis, hemorrhoids, and anal fissures. Its lead candidate, EB-01, is indicated for Allergic Contact Dermatitis and is already in Phase II clinical studies. The candidates in Phase I are EB-05, indicated for Irritant Contact Dermatitis, EB-02, for hemorrhoids, and EB-04, for Anal Fissures.
- Feb 2025Post IPO$15M
- Nov 2022Post IPO$3M
- Feb 2021Grant (prize money)—
- Sep 2017Post IPO$7M
#7
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
- Feb 2025Series A$7M
#8
Series A · Saint laurent, Quebec · founded 2017 · 8 employees$8.1Mraised▾
Developer of targeted therapies modulating membrane receptors for autoimmune diseases. It designs therapies through precision-targeting of key receptors. The company's development programs focus on treating inflammatory autoimmune conditions. It utilizes innovative chemistry to design modulators. The company has a multidisciplinary team focused on drug development. It has a clinical advisory board and a scientific advisory board.
- Sep 2024Series A$8.1M
- Jun 2020Seed—
#9
Seed · Montreal, Quebec · founded 2023$30Mraised▾
Developer of modulating biotherapeutics to address cancer and autoimmune diseases. It has AbiLeap discovery engine that combines continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies across cancer and autoimmune applications. The pipeline includes Leap 1121 for auti-immune disease, Leap 1009 and 1030 for solid tumors.
- Jun 2024Seed$18M
- Dec 2023Seed$12M
#10
Public · Toronto, Ontario · founded 1999 · 70 employees$36.7Mraised▾
Developer of multiplexed tests and automated systems for biological testing. The company's proprietary Ig_plex technology provides laboratories and clinical research organizations with the ability to simultaneous, automated analyses of customized multiple biomarkers down to the isotype and subclass level. The products include RALI-dx COVID-19 severity triage tests, home testing kits, and lung inflammation diagnostic tests.
- Dec 2022Post IPO$744.8K
- Nov 2021Post IPO$489.6K
- Nov 2021Post IPO$3.6M
- Jun 2021Post IPO$3.9M
#11
Public · Vancouver, British Columbia · founded 2012 · 560 employees$115Mraised▾
AI-enabled platform for antibodies discovery. The company has developed Celium which is an antibody visualization software and suite of proprietary microfluidic single-cell assays used for antibody screening. The company uses its proprietary repertoire sequencing technologies with functional data from single B cells to annotate immune repertoires. It has also developed its proprietary humanized mouse platform for the development of humanized antibodies.
- Jun 2021Post IPO—
- May 2020Grant (prize money)$124M
- Mar 2020Series B$105M
- Aug 2018Series A$10M
#12
Series C · Vancouver, British Columbia · founded 2007 · 22 employees$29.8Mraised▾
Qu Biologics is a clinical-stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). It aims to restore immune function and has potentially broad applicability across a wide variety of chronic diseases. The company currently has three clinical trials in Crohn's disease (Phase 2b), ulcerative colitis (Phase 2a), and lung cancer (Phase 2a).
- Mar 2022Series C$12M
- Dec 2020Grant (prize money)—
- Dec 2020Series B$8M
- May 2018Series A$48.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth rising
How research on Immunology & Immunotherapy is moving in Canada
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,374 Canada-affiliated papers.
- Ministry of Education188
- Princess Margaret Cancer Centre97
- University of Toronto89
- McGill University78
- Institute of Cancer Research77
- Immune system6→142
- Cancer immunotherapy1→44
- Cancer2→39
- Cancer research1→37
- T cell2→29
- Immune system10→208
- Cancer3→88
- Tumor microenvironment1→74
- Cancer research6→63
- Internal medicine5→60
- Immune system4→74
- Cancer1→40
- Disease1→35
- Oncology3→27
- Chimeric antigen receptor1→22
Where immunology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in Canada
Canada immunology patent filing is cooling — 351 filings from 355 assignees (2016–2025), led by UNIV Health Network, UTI, UNIV British Columbia; annual filings 33→25.
- UNIV Health Network43
- UTI39
- UNIV British Columbia30
- Prometic Biosciences29
- Immunovaccine Technologies29
- UNIV Arkansas28
- UNIV Guelph26
- Texas A & M UNIV SYS26
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.